Search Results

You searched for : treatmentforlungcancer

	PFIZERâ€™S XALKORI APPROVED BY USFDA FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN AND YOUNG ADULTS XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people ... Jan 15
	Pfizer's LORBRENA sNDA in previously untreated ALK-positive lung cancer accepted for priority review by U.S. FDA LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address ... Dec 29
	RESULTS FROM PHASE 3 CROWN TRIAL OF PFIZERâ€™S LORBRENA IN PREVIOUSLY UNTREATED ALK-POSITIVE LUNG CANCER PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE ... Nov 19
	Galera Therapeutics announces dosing of first patient for non-small cell lung cancer Galera Therapeutics announces dosing of first patient in the phase 1/2 GRECO-1 clinical trial of GC4711 in combination with SBRT for non-small ... Oct 23
	Blueprint Medicines receives FDA approval of Gavreto for lung cancer GAVRETO, the only once-daily RET-targeted therapy, demonstrated durable efficacy, with complete responses in a subset of patients ... Sep 05
5 Matching result(s) found!

-Advertisements-

Trending Now
	Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
	International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
	The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
	Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
	Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
	In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
	Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
	Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
	10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
	Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
	The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
	Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
	A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
	The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
	ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
	The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
	Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
	Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
	AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
	Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024

Search Results

PFIZERâ€™S XALKORI APPROVED BY USFDA FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN AND YOUNG ADULTS

Pfizer's LORBRENA sNDA in previously untreated ALK-positive lung cancer accepted for priority review by U.S. FDA

RESULTS FROM PHASE 3 CROWN TRIAL OF PFIZERâ€™S LORBRENA IN PREVIOUSLY UNTREATED ALK-POSITIVE LUNG CANCER PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Galera Therapeutics announces dosing of first patient for non-small cell lung cancer

Blueprint Medicines receives FDA approval of Gavreto for lung cancer

Trending Now